An interventional study of Transpara software in Breast Cancer, sponsored by Centre Antoine Lacassagne. Not yet recruiting at 2 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Centre Antoine Lacassagne · Not applicable, Interventional, and Screening
to evaluate the diagnostic performance of radiologists using the Transpara™ Incepto® software to interpret 2D mammograms with tomosynthesis as part of breast cancer screening
12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.
This study's planned enrollment of 1,222 is above the median of 72 across 9,494 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Centre Antoine Lacassagne is the lead sponsor of 66 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
use of artificial intelligence software for breast cancer screening
Device: Transpara software
use of transpara software for breast cancer screening
Sensitivity and specificity (diagnostic performance) of radiologist using the Transpara software
Medical conclusion of radiologist using the Transpara software at baseline compared to radiologist's decision alone at 2 years, or the result of the biopsy (positive during the follow-up period or negative at 2 years).
Time frame: 2 years
Rate of change in care following the use of the software Transpara by radiologist compared to the decision taken before by the radiologist alone
Rate of change in care following the use of the software Transpara by radiologist compared to the decision taken before by the radiologist alone
Time frame: Baseline
Diagnostic performance of radiologist alone and radiologist using the Transpara software
Compare the diagnostic performance of the radiologist working alone and the radiologist using the software at baseline
Time frame: Baseline
Radiologist evaluation false-positive rate obtained by radiologist using the Transpara software
To assess the false-positive rate generated by the radiologist using the Transpara™ Incepto software
Time frame: Baseline
Adverses events assessed by CTCAE 6.0
To assess adverse events associated with additional diagnostic investigations prompted by the use of the Transpara™ Incepto® software.
Time frame: 2 years
comparaison of diagnosis performance of radiologist alone and radiologist using the Transpara software
To compare the diagnostic performance of the Transpara™ Incepto® software with that of the radiologist alone.
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Antoine Lacassagne